Shire to undertake more study of ProAmatine
This article was originally published in Scrip
Executive Summary
Shire said on 2 December that it plans to conduct two trials of ProAmatine (midodrine) to meet requirements for the accelerated approval the drug's new drug application (NDA) was granted in 1996 by the US FDA as a treatment for patients with symptomatic orthostatic hypotension (SOH), a condition that affects about 60,000 people in the US causing a sudden decrease in blood pressure attributed to cardiovascular, endocrine or neurological disorders.